Our Latest News
Paris 2024 Partnership
March 28, 2024
The Meningitis Flag Awarded The Impact 2024 Label
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
Sanofi X Paris 2024
We’re proud to be premium partner of Paris 2024.
Science and sport aren’t that different. Just like athletes do, we overcome setbacks to keep moving forward, not just for ourselves, but for our patients, colleagues, families and friends.
About Us
Who We Are
We are an innovative global healthcare company.
Our Pipeline
6
Therapeutic areas
83
Compounds in clinical development
28
Clinical trials in phase 3
Explore Career Opportunities
You'll be surprised what you can achieve at Sanofi. Discover your future here.
Our Latest Press Releases
March 22, 2024
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
March 11, 2024
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
February 24, 2024
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
February 24, 2024
Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma